NCT03767023

Brief Summary

Aorta Abdominal aneurism (AAA) is a chronic degenerative disorder leading to the dilation and eventually to the rupture of the aortic wall. The pathology presents risk factors such as aging, atherosclerosis, male gender, cigarette smoking, pulmonary emphysema and high blood pressure.The vascular wall destruction is characterized by a remodeling of the extracellular matrix (ECM), the presence of an inflammatory infiltrate of macrophages and lymphocytes associated increase in production of MMPs. A similar destruction mechanisms is found in periodontitis a chronic inflammatory diseases characterized by gram-negative bacteria species that are able to degrade ECM of the tooth supporting tissues and leading finally to tooth loss .Moreover, relationships between periodontitis and cardiovascular disease have already been demonstrated. These associations are considered to be initiated by transient or prolonged bacteremia due to dissemination of oral bacteria or their products into the bloodstream . The periopathogens, more specifically Porphyromonas gingivalis (Pg), were observed in atherosclerosis and aneurysm specimens as well as in coronary heart disease and endocarditis The association between periodontitis and Abdominal Aortic Aneurysms (AAA) has not often been studied especially from a clinical aspect. The mechanisms that induce the initiation, the development or the recurrence and the rupture of AAA after a period of quiescence not well studied and are therefore still unknown. The aim of this clinical observational case controlled study is to search for a possible relationship between periodontal disease and rapid growth of AAA. Patients presenting stable or unstable AAA will be screened for the degree of periodontitis, for the type of oral microbiology and periodontopathogen markers present in the blood stream.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
61

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Feb 2015

Typical duration for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2015

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2015

Completed
2.8 years until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2018

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

October 26, 2018

Completed
1 month until next milestone

First Posted

Study publicly available on registry

December 6, 2018

Completed
Last Updated

December 14, 2018

Status Verified

December 1, 2018

Enrollment Period

4 months

First QC Date

October 26, 2018

Last Update Submit

December 12, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • pocked depth correlated with AAA stability

    Periodontal clinical parameters such as pocked depth (PD, millimeter) will be correlated with AAA stability.

    june 2017

Secondary Outcomes (1)

  • pocked depth correlated with abdominal aortic aneurysm diametres such as anterior -posterior

    March 2018

Study Arms (2)

Stable AAA

= patients with a small abdominal aortic aneursym diameter \< 55 mm "

Other: cross sectional

instable AAA

=patients with a large abdominal aortic aneursym diameter \> 55 mm and/or AAA with rapid growth who needs open surgery or EndoVascular Aneurysm Repair "EVAR

Other: cross sectional

Interventions

Stable AAAinstable AAA

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients from the Cardiovascular Surgery Department, University Hospital of Liège (Belgium) and presenting AAA were screened in order to include 31 patients in each group (stable versus instable AAA) according to the sample size calculation. Sixty-two patients were therefore included according to the following inclusion and exclusion criteria:

You may qualify if:

  • AAA
  • dentulous
  • ability to come in Hospital

You may not qualify if:

  • diseases of connective tissue: rheumatoid arthritis, systemic lupus erythematosus, systemic sclerodermia, Crohn disease, Marfan syndrome, Heler Danlos syndrome, polymyosite/dermatomyosite, mix connectivite (MCDT)
  • aneurysms of the lower limbs (femoral or popliteal)
  • contraindication to the scanner
  • participation of another clinical trial 30 days before baseline
  • patient with risk oslerien
  • obese patients (BMI ≥ 30 kg/m2)
  • immunosuppressant drugs or chemotherapy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Biospecimen

Retention: SAMPLES WITHOUT DNA

saliva, sub-gingival and supra-gingival samples

MeSH Terms

Conditions

Periodontitis

Interventions

Cross-Sectional Studies

Condition Hierarchy (Ancestors)

Periodontal DiseasesMouth DiseasesStomatognathic Diseases

Intervention Hierarchy (Ancestors)

Epidemiologic StudiesEpidemiologic Study CharacteristicsEpidemiologic MethodsInvestigative TechniquesHealth Care Evaluation MechanismsQuality of Health CareHealth Care Quality, Access, and EvaluationPublic HealthEnvironment and Public Health

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Doctor of Dental Surgery (DDS), Master of sciences (MS), PhD student

Study Record Dates

First Submitted

October 26, 2018

First Posted

December 6, 2018

Study Start

February 1, 2015

Primary Completion

June 1, 2015

Study Completion

March 1, 2018

Last Updated

December 14, 2018

Record last verified: 2018-12